MoonLake Immunotherapeutics MLTX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/17/24 EDT
39.75UNCH (UNCH)
Volume
2,606,070
Close
39.75quote price arrow down-1.11 (-2.72%)
Volume
404,249
52 week range
24.31 - 64.98
Loading...
  • Open40.84
  • Day High40.84
  • Day Low39.44
  • Prev Close40.86
  • 52 Week High64.98
  • 52 Week High Date02/12/24
  • 52 Week Low24.31
  • 52 Week Low Date06/13/23

Key Stats

  • Market Cap2.539B
  • Shares Out63.87M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta1.24
  • YTD % Change-34.18

KEY STATS

  • Open40.84
  • Day High40.84
  • Day Low39.44
  • Prev Close40.86
  • 52 Week High64.98
  • 52 Week High Date02/12/24
  • 52 Week Low24.31
  • 52 Week Low Date06/13/23
  • Market Cap2.539B
  • Shares Out63.87M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta1.24
  • YTD % Change-34.18

RATIOS/PROFITABILITY

  • EPS (TTM)-0.75
  • P/E (TTM)-52.99
  • Fwd P/E (NTM)-31.83
  • EBITDA (TTM)-60.979M
  • ROE (TTM)-13.92%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/08/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On MoonLake Immunotherapeutics

 

Profile

MORE
MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced...
Simon Sturge
Independent Chairman of the Board
Jorge Santos Da Silva
Chief Executive Officer, Director
Matthias Bodenstedt
Chief Financial Officer
Address
Dorfstrasse 29
Zug, ZUG
6300
Switzerland

Top Peers

SYMBOLLASTCHG%CHG
APGE
Apogee Therapeutics Inc
50.31-3.44-6.40%
JANX
Janux Therapeutics Inc
47.10-0.41-0.86%
CLDX
Celldex Therapeutics Inc
38.21-1.73-4.33%
RNA
Avidity Biosciences Inc
29.50+0.78+2.72%
MRUS
Merus NV
43.91-1.11-2.47%